- Home
- CADL vs IMMX Comparison
CADL vs IMMX Comparison
Compare CADL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | IMMX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 306.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CADL | IMMX |
|---|---|---|
| Price | $6.24 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $19.43 | $12.00 |
| AVG Volume (30 Days) | 706.6K | ★ 960.0K |
| Earning Date | 03-12-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $1.34 |
| 52 Week High | $13.68 | $7.73 |
Technical Indicators
Market Signals| Indicator | CADL | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 55.86 |
| Support Level | $5.88 | $4.54 |
| Resistance Level | $6.62 | $5.09 |
| Average True Range (ATR) | 0.38 | 0.41 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 71.43 | 86.43 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.